• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Prasugrel Teva
    / Abic

    Active Ingredient
    Prasugrel 5, 10 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    28 ×5, 10 mg

    not in the basket chart


    One tablet a day. The tablet should not be chewed or crushed. Please refer to the license holder for further details.


    Prasugrel Teva, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI] undergoing primary or delayed percutaneous coronary intervention (PCI).
    The increased efficacy should be balanced with the increased risk in patients with bleeding tendency in those who had TIA/CVA in the past and in those above the age of 75 or weight below 60 kg.


    Hypersensitivity to the active substance or any of its excipients.
    Patients with active bleeding (such as bleeding from an ulcer in gastro intestinal system).
    Patients with history of a stroke or a transient ischemic attack (TIA).
    Patients with severe hepatic disease.

    Teva Pharmaceutical Industries Ltd, Israel